greeksoup/ stock research
Stock research / United States / AZN / Year to 31 December 2018

AstraZeneca PLC (AZN) annual results, year to 31 December 2018: revenue USD 22,090 million, from the 20-F

AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2018 it reported revenue of USD 22,090 million, down 1.7% on the year before. Its profit attributable to shareholders was USD 2,155 million, down 28.2%, and diluted earnings per share USD 1.70.

Revenue
USD 22,090 million
-1.7% on the year
FY2015FY2018
Operating margin
15.3%
16.4% a year earlier
FY2015FY2018
Net income
USD 2,155 million
-28.2% on the year
FY2015FY2018
Diluted EPS
USD 1.70
-28.3% on the year
FY2015FY2018

this yearthe year beforeIn US dollars as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2017Dec 2018
Revenue22,46522,090
Cost of sales4,3184,936
Gross profit18,14717,154
Research and development5,7575,932
Selling, general and administrative10,23310,031
Operating profit3,6773,387
Finance costs1,5081,419
Profit before tax2,2271,993
Income tax-641-57.0
Profit for the year2,8682,050
Profit attributable to shareholders3,0012,155
Filing20-F20-F
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2017Dec 2018
Diluted EPS2.371.70
Basic EPS2.371.70
Filing20-F20-F

USD per ordinary share, as filed.

Cash flow

Year toDec 2017Dec 2018
Cash from operations3,5782,618
Purchase of property, plant and equipment1,3261,043
Free cash flow2,2521,575
Cash from investing-2,328963
Cash from financing-2,936-2,044
Dividends paid3,5193,484
Filing20-F20-F

USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2017Dec 2018
Funded by
Equity attributable to shareholders14,96012,468
Non-controlling interests1,6821,576
Borrowings, as filed17,80719,113
Other liabilities28,90527,494
Total equity and liabilities63,35460,651
Owned
Property, plant and equipment7,6157,421
Goodwill11,82511,707
Other intangible assets26,18821,959
Cash and cash equivalents3,3244,831
Trade and other receivables5,0095,574
Inventories3,0352,890
Other assets6,3586,269
Total assets63,35460,651
Filing20-F20-F

USD million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2017Dec 2018
Gross margin80.8%77.7%
Operating margin16.4%15.3%
Net margin13.4%9.8%
Free cash flow margin10.0%7.1%
Return on year-end equity20.1%17.3%
Effective tax rate-28.8%-2.9%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2018, filed 16 February 2021: the filing. The figures are in US dollars as filed.